THE SHARE: Change: +0.01 SEK (+5.53%) / Price: 0.11 SEK / Nov 25, 2025, 5:29 pm (CET)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • Physiological Targeting
    • Functional Nanoparticles
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

Press Releases

Year

Language

Category

  • 24 Nov, 2025
    Spago Nanomedical announces outcome of oversubscribed rights issue Regulatory
  • 7 Nov, 2025
    The subscription period in Spago Nanomedical’s rights issue begins today
  • 6 Nov, 2025
    Spago Nanomedical publishes information document in connection with forthcoming rights issue
  • 29 Oct, 2025
    Spago Nanomedical resolves on a rights issue of approximately SEK 25 million to advance Tumorad Regulatory
  • 29 Oct, 2025
    Spago Nanomedical interim report January-September 2025 Regulatory

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2025 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications